Literature DB >> 31195867

Efficacy comparison of titrated oral solution of misoprostol and intravenous oxytocin on labour induction in women with full-term pregnancy.

Maryam Kashanian1, Noushin Eshraghi1, Maryam Rahimi1, Narges Sheikhansari2, Forough Javanmanesh1.   

Abstract

A double-blind randomised trial was conducted on women with gestational age of 40-42 weeks of pregnancy and Bishop score of more than 5. The first group received oxytocin infusion and the second group received a titrated oral solution of misoprostol. Then, the two groups were compared by the primary outcome (the number of deliveries in the first 24 hours of intervention). The two groups did not have any significant difference in maternal and gestational age at the time of intervention, primary Bishop score, parity and neonatal weight. The number of deliveries in the first 24 hours was greater in the misoprostol group. Duration of onset of intervention to proper contractions was longer in the misoprostol group. However, the number of deliveries between 6-12 hours, 12-18 hours and 18-24 hours after induction was greater in the misoprostol group. The incidence of tachysystole and meconium was greater in the misoprostol group.Impact statementWhat is already known on this subject? Labour induction is widely used where the continuation of pregnancy might be dangerous for the mother or the baby. Of the various methods used for induction, misoprostol which is a prostaglandin E1 analogue has been reviewed more in recent years. Misoprostol has various routes of administration but in most studies only vaginal administration has been evaluated, leaving us with limited data about oral administration.What do the results of this study add? Oral misoprostol is a suitable method for labour induction and can be used as an alternative to oxytocin.What are the implications of these findings for clinical practice and/or further research? Misoprostol is not expensive, has a long shelf life, accessible in underdeveloped countries and rural areas and has several routes of administrations such as oral, sublingual and vaginal. Despite the fact that the oral route of misoprostol has a fast absorption and easier administration, there are relatively few studies assessing the the use of the oral route of misoprostol. Misoprostol is a suitable method for Labour induction and it has the potentials of being used as an alternative for oxytocin, however, the optimum dosages, the preferred route of administration, the maximum dose, the maximum time for administration, and maternal and neonatal safety should be studied more.

Entities:  

Keywords:  Labour induction; caesarean section; delivery; misoprostol; oxytocin; pregnancy; prostaglandin E1; vaginal delivery

Mesh:

Substances:

Year:  2019        PMID: 31195867     DOI: 10.1080/01443615.2019.1587598

Source DB:  PubMed          Journal:  J Obstet Gynaecol        ISSN: 0144-3615            Impact factor:   1.246


  4 in total

1.  Prediction of Preterm Delivery by Ultrasound Measurement of Cervical Length and Funneling Changes of the Cervix in Pregnant Women with Preterm Labor at 28-34 weeks of Gestation.

Authors:  Eshraghi Nooshin; Mohamadianamiri Mahdiss; Rahimi Maryam; Shafei-Nia Amineh; Noei Teymoordash Somayyeh
Journal:  J Med Life       Date:  2020 Oct-Dec

2.  Sublingual Misoprostol versus Oxytocin to Induce Labor in Term Premature Rupture of Membranes in Pregnant Women: A Randomized Single-Blind Controlled Trial.

Authors:  Suchada Unthanan; Kanyarat Petcharat; Sinart Prommas; Buppa Smanchat; Kornkarn Bhamarapravatana; Komsun Suwannarurk
Journal:  Biomed Res Int       Date:  2022-02-13       Impact factor: 3.411

3.  Low-dose oral misoprostol for induction of labour.

Authors:  Robbie S Kerr; Nimisha Kumar; Myfanwy J Williams; Anna Cuthbert; Nasreen Aflaifel; David M Haas; Andrew D Weeks
Journal:  Cochrane Database Syst Rev       Date:  2021-06-22

Review 4.  The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach.

Authors:  Sahar Najafi; Elham Rajaei; Rezvan Moallemian; Forough Nokhostin
Journal:  Clin Rheumatol       Date:  2020-09-03       Impact factor: 3.650

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.